Neurometer ^®Neuroselective Diagnostic Sensory Evaluation

More than 30 years after leaving the laboratory for clinical applications ranging from Podiatry toNeurology and dozens of other specialties in-between, the Neurometer^®evaluation continues to provideunique diagnostic measures of sensory nerve conduction thresholds (sNCT™s). The most widely used

sNCT™ measure is Current Perception Threshold (CPT ) which is the minimum amount of painlessneuroselective electrical stimulus that consistently elicits a nerve response.

The Neurometer generates a constant current stimulus by monitoring and compensating for tissueimpedance variations. The stimulus evokes responses that quantify the functional integrity of each of the three major sub-populations of sensory nerve fibers. Specifically, A , A & C fiber groups are

âä

selectively stimulated by sinusoid waveform currents of 2000 Hz, 250 Hz and 5 Hz respectively. Usingsmall surface electrodes, this test generates discrete double-blinded CPT measures (p<0.006) representing minimum detectable current intensities (+/-20 ìAmp.) for each fiber type. Scientific publications documenting all the statements in this document are referenced at www.neurotron.com.

Mucosa & Skin Progressive Neuropathy

Illustrated nerve fiber types: A_â(green), A_ä(blue) & C (red) fibers

Advantages of the Neurometer Evaluation

Common metabolic/toxic and progressive neuropathies affect sensory nerves before motor nerves.Affected sensory nerves pass through reversible stages of hyperesthesia (often sub-clinical) thenhypoesthesia and anesthesia. These sensory impairments occur in specific nerve fiber sub-populations.CPT studies have the unique capacity to evaluate the full spectrum of sensory nerve function in all themajor fiber sub-populations. Patients are frequently asymptomatic in the earliest stages. The earliest stage of the pathologic process is usually the easiest phase to effectively intervene. The Neurometer detects hyperesthetic sensory neuropathy in non-diabetics with impaired glucose tolerance and innon-diabetic obese individuals. This ability to detect subclinical abnormalities in conditions known tocarry a high risk of polyneuropathy is a tremendous clinical diagnostic advantage. It also detects thehypoesthesia of advanced neuropathic conditions as well as nerve regeneration.

Publications confirm that sensory impairments ranging from polyneuropathies (diabetic, demyelinating, toxic) to compressive lesions (Carpal Tunnel Syndrome), radiculopathies, spinal cord lesions aswell as regeneration may be neuroselectively evaluated. Additional publications have confirmed the utility of the application of Neurometer^®technology in pharmaceutical/cosmetic, and laboratory animal research.

Performing a Neurometer^® Electrodiagnostic Evaluation

Painless standardized automated double-blind testing methodology is used to determine the CPT.It is based on the same psycho-physical principles used in routine hearing tests. The painless stimulus is characterized as “tingling”, “prickling”, or “buzzing”. Qualitative measures such as warm, cold, vibration, touch etc. are not a factor.

Electrodes are positioned at the prescribed test site and held in place with tape. Directions for the technician are displayed on the LCD screen. The subject is instructed to press a button until a stimulusis detected at the site of the electrode(s) and then release the button. At this point, the CPT measure isverified using Compliance Guard^®software. This effectively monitors responses for consistency. CPTmeasures are the printed or sent directly to a computer for storage and software classification bycomparison to a validated normative database. A narrative patient report may be generated.

Background: Neurotron, Inc., founded in 1981, in Baltimore, MD, USA designs and developsNeurometer electrodiagnostic devices. The Neurometer emerged from laboratory studies at McGillUniversity, Montreal, PQ, Canada and clinical research at the Johns Hopkins University School ofMedicine, Baltimore. FDA registered in 1986, Neurometer ^®technology had the unique distinction of being the worlds first neuroselective electrodiagnostic device. It was also the first commerciallymarketed clinical neuro-diagnostic device that included validated evaluation software that graded theclinical severity of detected abnormalities based on established normative values and generated anarrative report. In 2010, a new version of the Neuval^®Database Software was released to permit the software to input test data directly from the device. Neurometer^®devices may be interfaced for directcontrol by fMRI or PET imaging control systems. Computer control permits audio and external triggercontrol and in vitro physiological studies. Applications of Neurometer^®technology include more that24 clinical specialties, as well as pharmaceutical, cosmetic and laboratory animal testing applications.More than one million painless Neurometer studies have been conducted with over 800 scientific peer-reviewed publications. These affirm that this automated electrodiagnostic procedure objectively andselectively quantifies the functioning of both unmyelinated and myelinated sensory nerve fibers at anycutaneous/mucosal/dental test site. The Neurometer has been useful in guiding clinicians to choose themost appropriate therapy and for monitoring and evaluating interventions.

Polyneuropathy Diagnosis: Anatomic & Neuroselective

Mapping Polyneuropathy - Axonal vs Demyelinating

Most metabolic and toxic neuropathies typically affect sensory nervesbefore motor nerves and present with a dying back distribution in the tips of thetoes first and later the fingers. Mapping the distribution of sensory impairmentresulting from polyneuropathy and noting the type of axonal dysfunctionpermits the differential diagnosis of diffuse demyelinating vs distal axonalpolyneuropathies. CPT measures from the big toe (A) are generally the first tobe affected, ranging from the earliest hyperesthetic stage to the advancedhypoestheticcondition. Normalsensation atproximaltestsites (B, C) confirmsthe clinical diagnosis of distal dying back polyneuropathy. In contrast, demyelinating polyneuropathies typically affect both proximal and distal CPTmeasures associated with myelinated fiber function (2000 Hz and 250 HzCPTs) but not measures associated with unmyelinated fiber function (5 Hz

_CPTs).Polyneuropathy Test Sites

CPT testing at the big toe incorporates both the superficial and the deep peroneal nerves (4th and 5thlumbar dermatomes respectively, site A above). This neurological overlap prevents focal nerve lesionsor mono-radiculopathies from affecting the CPT measures at this site. Conversely, symmetrical dyingback polyneuropathies affecting both the superficial and deep peroneal nerves are easily detectable atthis location.

Upper Extremity Differential Diagnosis

Screening for Carpal Tunnel Syndrome (CTS) is conducted at the distal phalange of the index finger(B). This site is also sensitive to vibration neuropathy (neuroselective for myelinated fibers). Guyon'scanal syndrome, may be detected through a comparison of the CPT measures from a digital ulnar nerve

(E) and palmar ulnar nerve (J). Upper /Lower Brachial Plexopathy is evaluated by noting the distribution of impairment.

Carpal Tunnel Syndrome (CTS)

Early CTS is associated with hyperesthetic CPTs (abnormally low electrical excitability) reflectinginflamed nerves that have not lost their functioning. Advanced CTS, associated with a loss of median nerve function, is associated with hypoesthetic (abnormally high) CPTs. The combination of a sensoryimpairment detected at the distal phalange of the index finger (Site B), combined with normal CPTmeasures from the ulnar nerve (5th finger, Site E) and palmar branch of the median nerve (Site I),objectively confirms the clinical diagnosis of CTS. The CPT evaluation can detect CTS in the presenceof a polyneuropathy. This electrodiagnostic procedure confirms the recovery of median nerve functionfollowing conservative or surgical treatment of CTS.

Upper Extremity Radiculopathy^{CPT Dermatome Test Sites}and Spinal Pathology

CPT measures quantify the severity of a radiculopathy. Thistype of diagnostic evaluation is conducted along a dermatomaldistribution. Further confirmation of a radiculopathic sensoryimpairment would include more proximal testing in the samedermatomes. Abnormal CPT measures caused by radiculopathy,meylopathy or conditions such as syringomyelia will be confined to a dermatomal and neuroselective distribution.

Lower Extremity Differential Diagnosis

Radiculopathy, Myelopathy & Focal Lesions

Radicular pain can mimic the pain of peripheral neuropathy,peripheral arterial disease or a focal lesion. Sensory impairmentsresulting from radiculopathy will affect the lower extremityalong a dermatomal distribution. Testing the same dermatomeat distal and proximal locations (innervated by different nerves, e.g., sites illustrated below: I-Peroneal and J-SaphenousNerves) or the same peripheral nerve in different dermatomes(e.g., sites I-L4 and H-L5) can help confirm a suspectedradiculopathy. The finding of a peripheral sensory impairmentsmeasured from several toes, combined with normal CPTs observed at proximal locations within the same dermatomesuggests that the lesion involves a peripheral and not a spinal nerve. Spinal lesions or myelopathy will result in a segmentalsensory impairment where all dermatomes below the level of thelesion are impaired.

_{Dermatome Cutaneous N.}Standardized CPT Test Sites (Norms Established) _{Herniated Disc}

Dental, Mucosal & Genital CPT Measures

Dental testing includes tooth measures and oral mucosal measures. Neurometer measures have proven useful for uro-gyn and pharmaceutical studies as well as for differentialdiagnostic applications. Experimental catheter electrodes for oral, urethral (proximal andmid) and , bladder, vaginal/anal applications and other specialized electrodes are availablefor research.

Urethral & Bladder Catheter Electrode with Lumen (12 Fr)(positioning balloon inflated, electrode is black)

Neurometer^® Device Testing

Test results are evaluated using the Neuval ^®Windows^® software. The reports include a grading of the functional integrity for the specific nerves and their sub-fiber groups and a summary. The findings arebased upon range, within-site and between-sites ratio analyses through comparison to a database ofclinically established normative values. Neurometer test modes include:

Clinical and Automated Current Perception Threshold (CPT) (p<0.05-0.006, resolution +/-20-50 ìA)

Painless Current Perception Threshold. Standardized automated double-blind determination mode requires 3-5

minutes (Clinical) to 5-10 minutes (Automated) per nerve/site. Ranged Current Perception Threshold (R-CPT) (p<0.05, Ranged CPT) -This mode allows neuroselective sensory threshold determination in approximately 2-3 minutes per nerve/site. Normative data is pre-programmed for 35 of the most common testing sites and a print out of the results immediately indicates if the subject’s measures are within these norms, hyperesthetic or hypoesthetic.

Pain Tolerance Threshold (PTT) The noninvasive atraumatic PTT mode permits the neuroselective evaluation

of pain. There are established PTT values for the finger and toe. Percentile Allodynia Testing This mode provides an automated PTT test completion based on normative PTT values established for the fingers and toes enables a less painful method to evaluate allodynia than the standardized PTT evaluation

Remote Computer & Audio Control Windows^®software is available for in vivo and in vitro physiological

research and laboratory applications. Animal Response Testing A non-invasive and harmless test permitting serial measures from the same site. The test may be used to assess any cutaneous or mucosal site using specialized electrodes for large or small animals. Evaluation of the concha of the ear gives direct access to brain stem neurons for CNS measures. Rat bladder electrodes are available.

Computer Interface for fMRI and PET Scans Custom fMRI cables are available from Neurotron, Inc.

Other Applications

Cosmetic The application of the Neurometer in cosmetics came from dentistry anddermatologystudies of sensitive teeth/oral mucosa and skin. Additionally the evaluation of theitch response has proved a useful measure. Synthetic Nerves, Stem Cells and Nerve Regeneration Neurometer measures have assisted in monitoring the recovery of sensation following various implants and transplants.

Environmental/Occupational Monitoring rice paddy farmers for pesticide and firefighters for PCB exposure as well as detecting the toxicity from arsenic, lead, other heavymetals and vibration exposure -the Neurometer has played a key role in environmentalmedicine.

Sports Medicine Providing objective automated measures of sensory functionof marathon runners on mountain tops and bicyclers in laboratories is madepossible because of the Neurometer's portability. The battery powered devicecomes with a customized padded crush resistant carrying case the is ideal forfield applications.

Medical Legal Neurometer evaluations have been recognized by courts in the USA and other countriesfor disability evaluation.

Neurometer^® Technology Comparison to Other Diagnostic Procedures

Capabilities and Features		Sensory Diagnostic Study
Capabilities and Features	CPT	SSEP	sNCV	Vib	Therm	Biopsy
Neuroselective Evaluation of All MajorSensory Fiber Types						
Evaluate Hyperesthesia and Hypoesthesia	
Test Any Cutaneous/Mucosal Site	
Localize Abnormal Sensory Function fromPeriphery to Spinal Cord		
Evaluate Early and Advanced Regeneration	
Detects Malingering						
Unaffected by Skin Thickness, ScarFormation or Edema and Skin Temperature	
Painless Measure					
Standardized Automated double blind study	

"While early intervention and treatment can be critical to slowing the disease's progression,most Americans don't recognize neuropathy's symptoms, which include weakness, numbness,tingling and pain, especially in the hands and feet. If ignored, the symptoms can intensifyto loss of sensation to unremitting pain. Neuropathy may be the most common disease inthe United States that you've never heard of. Many are even unaware that they have it".

Neuropathy Association, May 2008

Typical Sensory Nerve Fiber Subpopulations CPT Data: Site vs. Frequency

Sensory Nerve Fiber Types

Typical sensory nerves are composed of 3 major subpopulations of fibers. The large myelinated “A ” fibers conduct cutaneous touch and

pressure sensations, the small myelinated “A_ä” fibers conduct temperature, pressure and fast painsensations while the small unmyelinated “C”fibers comprising more than 80% of the total,primarily conduct temperature and slow pain sensations. The small myelinated, A fibers and

unmyelinated C fibers are responsible for conducting protective sensations that guard against serious injury. Unmyelinated C fibers also serve a critical role in the peripheral autonomicnervous system providing the innervation to thesmooth musculature. One third of the C-fibers are autonomic efferents. Clinical implications of theloss of large fiber function are not as severe as aloss of smaller fiber function.

Neuroselective Pathology

Clinical complications resulting from C fiberpolyneuropathy include foot ulceration, gangrene,cardiac and other types of autonomic dysfunction.The loss of protective function associated withsmall fiber “Painless” polyneuropathies is alsoassociated with “Painless” myocardial infarction.Standard clinical evaluations ranging from thesafety pin to the reflex hammer and sensory nerveconduction velocity tests do not evaluate C fiberfunction. The Neurometer provides an objectiveautomated non-invasive painless neuroselective evaluation of C fiber as well as A _äand A _âfiber functional integrity.

Both sensory and motor nerves are affected bymetabolic polyneuropathy. Common polyneuropathies are associated with sensory symptomsoccurring before weakness or motor impairment.Within the sensory nerve, various subpopulationsof fibers have differential susceptibilities to different types of neuropathies.

“Painless Neuropathy”
Loss of Protective Sensation

“Painless Neuropathy” is characterized by the selective loss of smaller fiber protectivesensation. An individual with this condition has intact large fiber touch sensation and may evenbe unaware of the neuropathy, greatly increasingthe risk of serious injury. For example, the individual may feel the”touch” sensation of stepping on a burning cigarette but not the “protective” sensation of the burn. Due to paininsensitivity, complications from the foot burnmay progress to infection and amputation. It is also important that the finger tips be evaluated todetermine the extent of this neuropathy.

C Fiber Neuropathy and

Autonomic Dysfunction

The impairment of autonomic function resultingfrom C fiber neuropathy can be a risk factor formortality among diabetic/uremic patients. The CPT evaluation has been reported by an NIHConsensus Conference to be a strong predictor ofmortality among kidney dialysis patients.

Neurometer^® Electrodiagnostic Evaluation
Neuroselectivity, Hyperesthesia and Pain

The Neurometer^®generates a constant alternating current (AC) stimulus to evoke nerve responses. The three major sub-populations ofsensory nerve fibers are defined by their morphologic, electrophysiologic and functional (e.g. painvs. non-pain transmission) characteristics. The smallest diameter unmyelinated fibers comprisegreater than eighty percent of the total fibers,possess the longest refractory periods and theslowest average conduction velocity (CV) of 1m/s. In contrast, large diameter myelinated fiberscomprise less than ten percent of the total fibers,have the briefest refractory periods and fastest average CV of 60 m/s. Neuroselectivity isachieved by using three different frequencies of anelectrical sinewave stimulus (2000 Hz, 250 Hzand 5 Hz), taking advantage of this waveform’sfrequency dependent rate of depolarization. Largediameter fibers can generate action potentials inresponse to the rapid 2000 Hz stimulus but smallfibers require several milliseconds of continuousdepolarization (i.e. low frequency stimulation,e.g., 5 Hz), to reach threshold potential. Largefibers will generate action potentials to the 5 Hzstimulus, but not at physiologically significantrates.1 Additionally, the quantity of electrons orcharge per depolarization of a 5 Hz sinewave (100msec) is 400 times the charge and duration of a2000 Hz sinewave depolarization (0.25 msec).Together, these factors result in the 2000 Hzstimulus selectively evoking physiologicallysignificant large myelinated fiber responses andthe 5 Hz stimulus selectively evoking physiologically significant unmyelinated fiber responses.

The neuroselective nature of the sinusoid waveform electrical stimulus was first demonstrated in a study comparing the application of a variety of waveform types on healthy individuals at Johns Hopkins in the 1980's. Neurometer measures have been compared withthe results of other physiological /imaging,diagnostic, histologic and pharmaceutical studies.These and other studies involving nerve regeneration, ischemia and neuroselective pathological conditions have corroborated the neuroselective nature of this stimulus. The CPT^®measures also have the unique ability of evaluating pathologies such as hyperesthesia and hypo-esthesia that may selectively occur in one or more subpopulations of sensory fibers while sparingthe others.

Sinusoid Waveform Stimuli. Top: 2 kHz and

5 Hz waveforms drawn to scale. Bottom: Amplitude vs Time for the two frequencies,depicting the sinusoidal waveform.

Hyperesthesia

Hyperesthesia, as measured by abnormallylow neuroselective Current Perception Threshold(CPT) measures, reflects an increased electricalexcitability of sensory nervous tissue for the evocation of responses. The resting membrane potential of the sensory nerve fiber increases as theresult of stresses such as hyperglycemia. An elevated resting membrane potential decreasesthe intensity of the excitatory electrical stimulusrequired to reach the threshold required to evokean action potential response. In other words, lesselectrical energy is required to evoke a neuronal response.

Hyperesthesia is reported in the earlystages of progressive neuropathy affecting bothpre-diabetics and newly diagnosed diabetics. Other early occurrences of hyperesthesia are present in alcoholism, Carpal Tunnel Syndrome(CTS) and radiculopathy. A different type of hyperesthesia results from chronic hereditarysensory neuropathies associated with lysosomalstorage disorders and primary biliary cirrhosis, demyelinating polyneuropathies and infectious conditions (eg. HIV, Lyme Disease). Other neurodiagnostic tests, (e.g. sensory nerve conduction velocity, quantitative tactile, vibration andthermal thresholds) are insensitive to the hyperesthetic condition which is often sub-clinical.

Pain Tolerance Threshold (PTT) and Allodynia

When the Neurometer ^®stimulus is administered at intensities greater than the painless CPT ^®sensory threshold it is possible to evoke painful sensation. Under patient control,the maximum tolerable intensity neuroselectivestimulus is defined as the Pain Tolerance Threshold (PTT`™). The PTT ™ has been demonstrated to be a reliable measure for the evaluation of pain and select analgesic agents.Allodynia is characterized by increased sensitivity to a non-noxious stimulus which the subject characterizes as "painful". Allodynia may beevaluated by neuroselective PTT ™ measures aswell as the less painful “Percentile AllyodyniaTest”. CPT^®hyperesthesia and PTT™ allodynia may occur as neuroselective and independent sensory conditions. For example, spinal opiates do not affect the 2000 Hz, 250 Hz or 5 Hz painless CPT ^®measures or the 2000 Hz and 250 Hz PTT™ measures but they selectively elevate 5Hz PTT™ measures in humans. Similar Neurometer neuroselective response measures have been reported from rats.

Direct Nerve Fiber Stimulation

Neurometer ^®CPT ^®and PTT™ measures are not receptor or end-organ mediated. The electrical stimulus bypasses these transducers anddirectly excites the nerve fibers. Skin freeze or burn lesions precipitate the local release of an“inflammatory broth” (e.g. bradykinins, prostaglandins, leukotrienes, substance P, etc.) which bind to receptors resulting in local sensory thermal and tactile threshold changes. Thermal allodynia (pain evoked by normally painless heatstimulus) and tactile allodynia (pain evoked by anormally painless tactile stimulus, e.g., Von Freyfilament stimulus) occurs with these lesions.Research has demonstrated that PTT™ electrical allodynia, however, does not occur with the skinfreeze model and other differences between these types of stimuli that may be due to their differentsite of stimulation, i.e., end-organ vs direct nervestimulation.

fMRI and Neurometer Pain

Functional magnetic resonance imaging studiesfrom the Massachusetts General Hospital havedemonstrated that heat pain and 5 Hz sNCT painincrease metabolic activity in the same areas ofthe brain; however, there is a habituation to the heat pain stimulus that does not occur with theelectrical pain stimulus. This and other fMRI related studies are cited at www.neurotron.com.

Reference Material

There are more than 800 peer reviewed publications utilizing Neurometer ^®technology. Documentation and bibliographies of publications are continuously updated at: www.neurotron.com.

Legal Notices: The Neurometer® device and/or the methods ofapplication are patented under one or more of the following patentsand international patents pending: US Nos. 4,305,402 &4,503,863, UK No 2,052,994, Canada No 1,157,526, Japan No

®®

3138428, Brazil No 9610321-3. Neurometer , CPT/Eagle ,

® ®®

Goldtrode and Softape , CPT , PTT ™ and sNCT ™ are registered and pending trademarks of Neurotron, Inc.

High Sensitivity

The sNCT/CPT procedure detects and quantifies all stages of neuropathy ranging from hyperesthesia to hypoesthesia and anesthesia. The built-in RCPT mode offers accelerated testing of selected distal sites.

High Reliability

The Neurometer^®NS3000^®uses a double blinded automated procedure to eliminate operator or patient influence (confirmed to p<0.006). Test results are not effected by edema or normal variations in skin thickness or temperature, so all measures can be evaluated through comparison to standardized, clinically established ranges of normative measures.

Test Any Cutaneous Site

Tests can be conducted on the face, the tips of the fingers or toes or at any cutaneous site on the body. Testing distal sites allows the earliest detection of dying back neuropathies. The painless stimulus allows testing on sites in sensitive areas like the face or genitalia.

Painless Neuroselective Stimulus

Each NS3000^®procedure uses three painless neuroselective stimuli to selectively evaluate both large and small fibers. The painless nature of the test encourages patient compliance with serial evaluations and allows testing of highly sensitive areas of the body It is ideal for testing children and others adverse to the discomfort associated with traditional electrodiagnostic tests.

Reliable, Accurate & Portable

The NS3000^®system is self calibrating and has a built-in procedure that assures the output stimulus and cable assembly are functioning properly and without distortion prior to examinations. The system is powered by a rechargeable battery and comes in a rugged carrying case for convenient testing almost anywhere.

Replaces Other Procedures

The Neurometer^®NS3000^®is the ideal replacement for imprecise, subjective tests using pinwheels and tuning forks and for older quantitative tests using vibratory (VT) or thermal (TT) stimuli or that measure velocity (sNCV).

Neurotron, Inc. • 2747 Geneva Court, Denver, CO 80238-3041 USA • www.neurotron.com Phone: (888) 804-5486 | (303) 316-0555 • Fax: (303) 557-6152 • Email: support@neurotron.com

provides a reproducible, non-invasive method for neuroselective evaluations of conditions like allo

dynia and analgesia. The external computer con

(sNCT) evaluations by determining Current Perception Threshold (CPT) measures. Neuroselective sinusoidal electrical stimuli quickly, painlessly and objectively quantify the conduction and functional integrity of the large and small myelinated and unmyelinated sensory nerve fibers. Easy operation, portability and versatile computer controlled testing modes provide standardized double blind automated sensory evaluations for clinical, occupational and research settings.

The Neurometer^®CPT/C can evaluate and document sensory nerve impairments at any cutaneous or mucosal site. The sNCT/CPT evaluation is extremely sensitive, detecting and quantifying hyperesthesia in early stage progressive neuropathy and hypoesthesia in more advanced conditions. The CPT/C conducts a full range of self-administered, automated, manual and programmable neuroselective sensory nerve evaluations in addition to the sNCT/CPT procedure. The fast and accurate RCPT mode allows individuals and groups to be quickly assessed for changes and abnormalities in sensory nerve function. The atraumatic Pain Tolerance Threshold (PTT) mode trol package adds programmable control functions to the CPT/C for creating automated atraumatic sensory evaluation procedures for both humans and laboratory animals. Special cabling also allows concurrent use of the CPT/C with fMRI and other imaging procedures and with bladder mucosal evaluations.

The Neurometer^®CPT/C stimulus is self-calibrating and patented circuitry maintains a constant current output that compensates for normal variations in skin thickness and impedance. Compliance Guard^®software monitors the consistency of patient responses assuring high reproducibility

and significant reliability (p<0.006). Neuval software, included with each device, performs a multidimensional analysis of CPT measures through comparison to clinically established healthy measures and generates a narrative laboratory report. Hundreds of peer reviewed publications and presentations establish the reliability of the sNCT/CPT examination. The Neurometer^®CPT/C is uniquely sensitive and effective for evaluating sensory nerve impairments,

For Additional Information on the Neurometer^®CPT/C, Contact:

NEUROTRON, INCORPORATED

INNOVATIVE MEDICAL TECHNOLOGY

2747 Geneva Court Denver, CO 80238-3041 • USA Phone: (888) 804-5486 • (303) 316-0555 Fax: (303) 557-6152 Email: support@neurotron.com Website: www.neurotron.com

Neurometer® Clinical and Research Update (2010-2011)

Neurometer ® Neuroselective Diagnostic Sensory Evaluation